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Abstract
Background: HIV genetic diversity implicates major challenges for the control of viral infection by the immune
system and for the identification of an effective immunotherapeutic strategy. With the present case report we
underline as HIV evolution could be effectively halted by early antiretroviral treatment (eART). Few cases supported
this evidence due to the difficulty of performing amplification and sequencing analysis in long-term viral suppressed
patients. Here, we reported the case of limited HIV-1 viral evolution over time in a successful early treated child.
Case presentation: A perinatally HIV-1 infected infant was treated within 7 weeks of age with zidovudine, lamivudine,
nevirapine and lopinavir/ritonavir. At antiretroviral treatment (ART) initiation HIV-1 viral load (VL) and CD4 percentage
were >500,000 copies/ml and 35%, respectively. Plasma genotypic resistance test showed a wild-type virus. The child
reached VL undetectability after 33 weeks of combination antiretroviral therapy (cART) since he maintained a stable VL
<40copies/ml. After 116 weeks on ART we were able to perform amplification and sequencing assay on the plasma
virus. At this time VL was <40 copies/ml and CD4 percentage was 40%. Again the genotypic resistance test revealed a
wild-type virus. The phylogenetic analysis performed on the HIV-1 pol sequences of the mother and the child revealed
that sequences clustered with C subtype reference strains and formed a monophyletic cluster distinct from the other C
sequences included in the analysis (bootstrap value >90%). Any major evolutionary divergence was detected.
Conclusions: eART limits the viral evolution avoiding the emergence of new viral variants. This result may have
important implications in host immune control and may sustain the challenge search of new personalized
immunotherapeutic approaches to achieve a prolonged viral remission.
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Background
HIV-1 infection is characterized by broad genetic diver-
sity and rapid evolution that influence the pathogenesis,
transmission and clinical management of the infection
[1]. Such high genetic variability represents also a major
drawback in the identification of an effective immuno-
therapeutic strategy. Genetically homogeneous virus
population has been found at birth in perinatally HIV in-
fected infants, in contrast to the heterogeneous virus
populations often found in their infected mothers [2].
Similarly, a uniform viral population has been observed
in newly infected adults short after transmission [3].
These observations led to the hypothesis that an early
intervention with cARTcould limit viral evolution. Indeed,
the homogeneity of viral sequences in HIV infected indi-
viduals treated during early infection compared with
higher diversity in late treated patients has been recently
confirmed in adult populations [4–6]. Although the rela-
tionship between the viral evolutionary dynamics and tim-
ing of treatment has been explored to some extent in
adult less is known about this relationship during paediat-
ric HIV-1 infection [7]. This is mostly due to the difficulty
of performing amplification and sequencing analysis with
* Correspondence: paolo.palma@opbg.net; stefania.bernardi@opbg.net
†Equal contributors
1Academic Department of Pediatrics, Unit of Immune and Infectious
Diseases, Children’s Hospital Bambino Gesù, P.zza Sant’Onofrio, 4-00165
Rome, Italy
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Palma et al. BMC Infectious Diseases  (2016) 16:742 
DOI 10.1186/s12879-016-2092-z
limited volume of blood in perinatally HIV infected chil-
dren on viral suppression since infancy [7–9]. Here, we re-
ported the case of limited HIV-1 viral evolution in an
early treated child with stable viral VL <40 copies/ml in
which we were able to amplify and analyze HIV-1 pol
sequences at different time points.
Case report
An infant was born by elective caesarean section, two
hours after membrane rupture at 38 weeks of gestation
to an HIV-1 infected woman who started a first line
ART with lamivudine, zidovudine and lopinavir/ritonavir
1 week before the delivery. Maternal VL at delivery was
203,686 copies/ml. Intrapartum antiretroviral prophy-
laxis with intravenous zidovudine was administered and
the child started postnatal prophylaxis with zidovudine
at 6 h of birth for 6 weeks. Breastfeeding was avoided.
Polymerase chain reaction (PCR) for genes GAG, POL,
and ENV performed at 6 weeks of life was positive and
his HIV-RNA VL was >500,000 copies/mL with CD4
lymphocyte percentage 35%.
The genotypic resistance test from both mother and
child didn’t show any transmitted drug resistance for PI,
NRTI or NNRTI drug classes. Based on these results, at
7 weeks of age cART was initiated. A four-drug regimen
of zidovudine, lamivudine, nevirapine and lopinavir/rito-
navir was selected according to the results of genotypic
resistance test. Plasma VL remained detectable till the
32th week from starting therapy despite an adequate ma-
ternal compliance with infant’s drugs and on subsequent
medical check the baby maintained undetectable HIV-1
RNA and CD4 T count within the range for age. At
48 weeks from starting therapy, ART was simplified by
suspending protease inhibitor. Concurrently to the VL
undetectability, HIV-1 antibodies were negative in the
child at 26, and 31 months of age. After 116 weeks on
cART, we were able to perform viral isolation and amp-
lification. At this time VL was stable <40 copies/ml
(ABBOTT) and CD4 percentage was 40%. A genotypic
resistance test for pol was re-performed and no-drug
resistance was found for a second time.
In order to clarify the epidemiological linkage and the
evolutionary divergence between mother and child HIV-
1 strains, a phylogenetic analysis was carried out on pol
sequences performed at different time points. In particular,
one pol sequence from plasma HIV-RNA and one pol se-
quence from PBMCs HIV-1 DNA obtained at the time of
partum and 2 years later, respectively, were available for
the mother. Two plasma pol sequences at the time of birth
and 2 years later (corresponding to the 116 week of ART),
were available for the child. To define the HIV-1 subtype
and the sequence inter-relationships between the mother/
child pair a neighbor joining (NJ) tree [10] was constructed
using a first dataset containing all pol sequences obtained
from the mother and child, HIV pol reference sequences,
and 396 full-length pol sequences (1,200 bp) obtained from
routine laboratory testing at the Virology Unit Hospital
“Tor Vergata”, from January 2012 to December 2014. The
reliability of the branching orders was assessed by boot-
strap analysis of 1000 replicates. Genetic distances were
calculated using MEGA 6.0 based on Kimura-2 parameter
(K2P) model [11]. To avoid potential contaminations iden-
tical sequences amplified in the same run were excluded.
Phylogenetic analysis by NJ method revealed that the
HIV-1 pol sequences from the mother/child pair clustered
together with C subtype reference strains, forming a mono-
phyletic cluster distinct from the other C sequences in-
cluded in the analysis (bootstrap value >90%) (Additional
file 1: Figure S1).
Once the HIV-1 subtype was assigned, the statistical
robustness of the monophyletic clade was confirmed also
by the ML tree, containing only C reference sequences
and 98 C isolates obtained from routine laboratory testing
(bootstrap value >85%) (Fig. 1). This was inferred by the
PhyML program (http://www.atgc-montpellier.fr/phyml/)
using the GTR + I + Γ nucleotide substitution model. The
simplest model that adequately fitted the sequence data
was selected according to the Akaike Information Criter-
ion (AIC) included in the MEGA package (version 6.0).
Robustness of the phylogenetic clades was evaluated by
bootstrap analysis (1000 replicates). The tree was rooted
using a midpoint rooting. Again, the 4 pol sequences from
the mother/child pair form a monophyletic cluster distinct
from all the other C sequences included in the analysis
(Fig. 1).
The extremely low mean genetic distance in pol region
characterizing pol sequences from the mother/child pair
compared to the ones from local unrelated non-cluster
C controls (pol: 0.0017, standard error [SE]:±0.001 vs
0.081, standard error [SE]:±0.004) confirmed the high
homology among mother and child sequences.
The phylogenetic analysis also revealed that the 2 se-
quences of the child clustered together and showed a
minimal evolutionary divergence among them (mean ±
SE:0.000090 ± 000087). This minimal evolutionary di-
vergence is sustained by a single nucleotide substitution
at position 231 of RT (C to T [F77F]).
Conclusions
HIV-1 populations in the blood of the newly infected
individuals are largely homogenous and evolve in a
manner consistent with exponential viral replication
[3]. Thus, starting antiretroviral treatment during acute
infection can limit HIV viral evolution avoiding the
emergence of new viral variants. Recent studies in HIV
infected adults support this evidence [4–6] but few data
are available in the pediatric setting [7]. The present case
report highlights the impact of eART in limiting HIV
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genetic diversity over time in a perinatally HIV infected
child on stable viral suppression (<40 copies/ml). Our
result confirming those recently published in adults
[4–6], may have important implications for the future
defining of a personalized immunotherapeutic approach
[12]. To date, eART alone is not sufficient to induce a sus-
tained viral remission and additional immunotherapeutic
interventions should be considered [12]. An effective early
cART can prevent HIV-1 evolution modifying the natural
history of the infection from a rapidly evolving viral infec-
tion to a state of clonal persistence with a single or a few
variants. This restricted pool of variants can be more
easily targeted by autologous cytotoxic T-lymphocytes
(CTL) [13] or therapeutic vaccines induced strategies
[12, 14]. Further studies are needed in order to determine
whether limited HIV-1 evolution overtime can be associ-
ated with a higher likelihood to achieve viral remission [9].
Additional files
Additional file 1: Figure S1. Neighborg phylogenetic tree constructed
on the pol gene sequences of 400 isolates and additional 163 HIV-1 subtype
references. The bar at the bottom indicating 0.01 nucleotide substitution per
site. Bootstrap support >90% were showed along the branches. Isolates of
sutypes C are shown in red. The sequences involved in mother to child
transmission chain are in bold red. (PPTX 160 kb).
Fig. 1 Maximum likelihood phylogenetic tree constructed on the pol gene sequences of 102 isolates and additional 4 subtype C references. The tree
was rooted using the midpoint rooting method. Branch lenghts were estimated with the best fitting nucleotide substitution model (GTR + G + I)
according to a hierarchical likelihood ratio test. The bar at the bottom indicating 0.03 nucleotide substitution per site. The astericks (*) along a branch
represent bootstrap support >85%. The 4 C sequences belonged to mother to child transmission chain are shown in red and the cluster involving
them is in the gray box. The cartoon summarizes the timing of sampling
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